A marker combination related to postoperative prognosis of colorectal cancer and application and prediction system thereof
By combining gut microbiota and metabolomics biomarkers, a predictive model was constructed, which solved the problems of accuracy and specificity in predicting the risk of recurrence after colorectal cancer surgery, achieved efficient prognostic assessment, and improved the performance and stability of the predictive model.
CN122235339APending Publication Date: 2026-06-19NANKAI UNIV +1
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- NANKAI UNIV
- Filing Date
- 2026-03-31
- Publication Date
- 2026-06-19
Smart Images
Figure CN122235339A_ABST
Abstract
This invention belongs to the fields of bioinformatics and medical testing technology, specifically relating to a combination of biomarkers related to the postoperative prognosis of colorectal cancer and their application and prediction system. This invention, through 16S rRNA gene sequencing of tumor mucosal samples from colorectal cancer patients, combined with long-term postoperative follow-up data and screening, found that *Peptostreptococcus*, *Fusobacterium*, *Bacteroides*, *Porphyromonas*, and *Prevotella* are closely related to postoperative recurrence of colorectal cancer, with an AUC of 0.81 for assessing postoperative recurrence. Based on this, this invention conducts non-targeted metabolomics analysis, finding that combining alanine glutamate, putrescine, arginine, histidine, and sebacic acid with the above microbial biomarkers can improve the AUC to 0.91, significantly enhancing accuracy, specificity, and precision. This enables prognostic stratification of recurrence-free survival in colorectal cancer patients, demonstrating higher predictive efficacy and stability.
Need to check novelty before this filing date? Find Prior Art